<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Hosp Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Hosp Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">3587</journal-id><journal-id journal-id-type="pmc-domain">ejhp</journal-id><journal-id journal-id-type="publisher-id">ejhp</journal-id><journal-title-group><journal-title>European Journal of Hospital Pharmacy</journal-title></journal-title-group><issn pub-type="ppub">2047-9956</issn><issn pub-type="epub">2047-9964</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10447966</article-id><article-id pub-id-type="pmcid-ver">PMC10447966.1</article-id><article-id pub-id-type="pmcaid">10447966</article-id><article-id pub-id-type="pmcaiid">10447966</article-id><article-id pub-id-type="pmid">37142386</article-id><article-id pub-id-type="doi">10.1136/ejhpharm-2023-003715</article-id><article-id pub-id-type="publisher-id">ejhpharm-2023-003715</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>2344</subject></subj-group></article-categories><title-group><article-title>Medication-related problems in critical care survivors: a systematic review</article-title></title-group><contrib-group><contrib id="author-105174004" contrib-type="author"><name name-style="western"><surname>Short</surname><given-names initials="A">Abigail</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib id="author-105173095" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8206-6801</contrib-id><name name-style="western"><surname>McPeake</surname><given-names initials="J">Joanne</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib id="author-105174061" contrib-type="author"><name name-style="western"><surname>Andonovic</surname><given-names initials="M">Mark</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib id="author-105174091" contrib-type="author"><name name-style="western"><surname>McFee</surname><given-names initials="S">Stuart</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib id="author-105174106" contrib-type="author"><name name-style="western"><surname>Quasim</surname><given-names initials="T">Tara</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib id="author-105174137" contrib-type="author"><name name-style="western"><surname>Leyland</surname><given-names initials="A">Alastair</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib id="author-89315486" contrib-type="author"><name name-style="western"><surname>Shaw</surname><given-names initials="M">Martin</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib id="author-105174189" contrib-type="author"><name name-style="western"><surname>Iwashyna</surname><given-names initials="T">Theodore</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib id="author-65052346" contrib-type="author"><name name-style="western"><surname>MacTavish</surname><given-names initials="P">Pamela</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution specific-use="Ringgold_3309">NHS Forth Valley</institution>, <addr-line content-type="city">Stirling</addr-line>, <addr-line content-type="state">Stirling</addr-line>, <country>UK</country>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="department">The Healthcare Improvement Studies Institute</institution>, <institution specific-use="Ringgold_3526">University of Cambridge</institution>, <addr-line content-type="city">Cambridge</addr-line>, <country>UK</country>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="department">School of Medicine, Dentistry and Nursing</institution>, <institution specific-use="Ringgold_3526">University of Glasgow</institution>, <addr-line content-type="city">Glasgow</addr-line>, <country>UK</country>
</aff><aff id="aff4">
<label>4</label>
<institution specific-use="Ringgold_3529">NHS Greater Glasgow and Clyde</institution>, <addr-line content-type="city">Glasgow</addr-line>, <country>UK</country>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="department">MRC/CSO Social and Public Health Sciences Unit</institution>, <institution specific-use="Ringgold_223860">University of Glasgow</institution>, <addr-line content-type="city">Glasgow</addr-line>, <country>UK</country>
</aff><aff id="aff6">
<label>6</label>
<institution specific-use="Ringgold_1466">Johns Hopkins University</institution>, <addr-line content-type="city">Baltimore</addr-line>, <addr-line content-type="state">Maryland</addr-line>, <country>USA</country>
</aff><author-notes><corresp><label>Correspondence to</label> Dr Joanne McPeake, University of Glasgow, Glasgow G12 8QQ, UK; <email>joanne.mcpeake@glasgow.ac.uk</email></corresp><fn fn-type="other" id="fn9"><p>EAHP Statement 5: Patient Safety and Quality Assurance.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>4</day><month>5</month><year>2023</year></pub-date><volume>30</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">443907</issue-id><fpage>250</fpage><lpage>256</lpage><history><date date-type="received"><day>01</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>25</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-25 03:25:09.950"><day>25</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; European Association of Hospital Pharmacists 2023. Re-use permitted under CC BY. Published by BMJ.</copyright-statement><copyright-year>2023</copyright-year><ali:free_to_read/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2023-05-04">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ejhpharm-2023-003715.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="ejhpharm-2023-003715.pdf"/><abstract><sec><title>Objectives</title><p>There are numerous, often single centre discussions of assorted medication-related problems after hospital discharge in patients who survive critical illness. However, there has been little synthesis of the incidence of medication-related problems, the classes of medications most often studied, the factors that are associated with greater patient risk of such problems or interventions that can prevent them.</p></sec><sec><title>Methods</title><p>We undertook a systematic review to understand medication management and medication problems in critical care survivors in the hospital discharge period. We searched OVID Medline, Embase, PsychINFO, CINAHL and the Cochrane database (2001&#8211;2022). Two reviewers independently screened publications to identify studies that examined medication management at hospital discharge or thereafter in critical care survivors. We included randomised and non-randomised studies. We extracted data independently and in duplicate. Data extracted included medication type, medication-related problems and frequency of medication issues, alongside demographics such as study setting. Cohort study quality was assessed using the Newcastle Ottowa Score checklist. Data were analysed across medication categories.</p></sec><sec><title>Results</title><p>The database search initially retrieved 1180 studies; following the removal of duplicates and studies which did not fit the inclusion criteria, 47 papers were included. The quality of studies included varied. The outcomes measured and the timepoints at which data were captured also varied, which impacted the quality of data synthesis. Across the studies included, we found that as many as 80% of critically ill patients experienced medication-related problems in the posthospital discharge period. These issues included inappropriate continuation of newly prescribed drugs such as antipsychotics, gastrointestinal prophylaxis and analgesic medications, as well as inappropriate discontinuation of chronic disease medications, such as secondary prevention cardiac drugs.</p></sec><sec><title>Conclusions</title><p>Following critical illness, a high proportion of patients experience problems with their medications. These changes were present across multiple health systems. Further research is required to understand optimal medicine management across the full recovery trajectory of critical illness.</p></sec><sec><title>PROSPERO registration number</title><p>CRD42021255975.</p></sec></abstract><kwd-group><kwd>Critical Care</kwd><kwd>CLINICAL MEDICINE</kwd><kwd>PHYSICAL AND REHABILITATION MEDICINE</kwd><kwd>Quality of Health Care</kwd><kwd>CRITICAL CARE</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="funding-1"><funding-source><institution-wrap><institution>The Healthcare Improvement Studies</institution></institution-wrap></funding-source><award-id>PD-2019-02-16</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><sec><title>WHAT IS ALREADY KNOWN ABOUT THIS TOPIC</title><list list-type="bullet"><list-item><p>Survivors of critical illness experience multiple transitions of care following critical care discharge. As a result, there can be subsequent interruptions and disruptions with medication management.</p></list-item></list></sec><sec><title>WHAT THIS STUDY ADDS</title><list list-type="bullet"><list-item><p>As many as 80% of critical care survivors can experience problems with medication management during recovery. This includes unintentional discontinuation of chronic disease medications in up to a quarter of patients; conversely, many patients are continued, often inappropriately, on acutely prescribed drugs.</p></list-item></list></sec><sec><title>HOW MIGHT THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</title><list list-type="bullet"><list-item><p>Further research is required to understand optimal medicine management across the full recovery trajectory of critical illness.</p></list-item></list></sec></boxed-text><sec id="s1"><title>BACKGROUND</title><p>Patients admitted to critical care can often experience both rapidly changing organ dysfunctions and multiple transitions of care.<xref rid="R1" ref-type="bibr">1</xref> Both factors place patients at risk for disruptions of medications.<xref rid="R2" ref-type="bibr">2 3</xref> Medication regimens at hospital discharge can differ from preadmission medications, and when these changes are not appropriately managed across transitions of care, it can lead to subsequent patient harm.<xref rid="R4" ref-type="bibr">4&#8211;6</xref>
</p><p>There are few standard guidelines as to how to prevent or detect-and-remediate afterwards, such disruptions in care. At present there are no published systematic reviews which attempt to synthesise key questions such as: how common are such medication-related problems after critical illness? Which medication classes are involved in these problems? Are some patients at greater risk? Moreover, there is no evidence summary examining what can be done to avoid patient harm from medication-related problems after a stay in the intensive care unit (ICU).</p><p>Therefore, we undertook a systematic review to understand medication management and medication problems in critical care survivors in the hospital discharge period. We hypothesised that there would be a broad spectrum of medication issues and challenges for survivors.</p></sec><sec sec-type="methods" id="s2"><title>METHODS</title><sec id="s2-1"><title>Search strategy</title><p>The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist was followed for reporting this systematic review.<xref rid="R7" ref-type="bibr">7</xref> The review protocol was registered with PROSPERO (CRD 42021255975).</p><p>PROSPERO and the Cochrane database were searched to ensure that no other systematic review was underway. One review was underway; this review aimed to examine the impact of a medication-related interventions during transitions of care between ICU settings and the general ward environment.<xref rid="R8" ref-type="bibr">8</xref> No review was examining the transition from hospital to home, or longer-term medication management in critical care survivors.</p><p>We electronically searched OVID Medline, EMBASE, PsychINFO, CINAHL and the Cochrane database. Our search took place on 20 July 2021, with an update undertaken on 31 August 2022. The search strategy, which was supported by an experienced librarian (SM), cross-referenced medicine management and critical illness with appropriate keywords and subject headings (see <xref rid="SP1" ref-type="supplementary-material">online supplemental file S1</xref> for full details). The search was limited to research published between 2001 and 2022. This date restriction was applied as the importance of medicine safety and adverse event reporting was highlighted via the Institute of Medicine&#8217;s seminal &#8216;To Err is Human<italic toggle="yes">&#8217;</italic> white paper in 2000, with subsequent widespread implementation of changes to medicines reconciliation internationally.<xref rid="R9" ref-type="bibr">9</xref>
</p><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/ejhpharm-2023-003715.supp1</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS1" xlink:href="ejhpharm-2023-003715supp001.pdf" content-type="local-data"/>
</p></supplementary-material></sec><sec id="s2-2"><title>Study selection</title><p>The research question was generated via the participants, interventions, comparisons and outcomes (PICO) model (<xref rid="T1" ref-type="table">table 1</xref>).<xref rid="R10" ref-type="bibr">10</xref>
</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>PICO model alongside design inclusion/exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</td><td align="left" valign="bottom" rowspan="1" colspan="1">Inclusion</td><td align="left" valign="bottom" rowspan="1" colspan="1">Exclusion</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Participants</td><td align="left" valign="top" rowspan="1" colspan="1">Patients admitted to critical care</td><td align="left" valign="top" rowspan="1" colspan="1">Patients without a critical care encounter</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interventions</td><td align="left" valign="top" rowspan="1" colspan="1">Any as per definition</td><td align="left" valign="top" rowspan="1" colspan="1">Studies that did not provide data on medicines at hospital discharge or in the posthospital discharge period</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Comparisons</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Outcomes</td><td align="left" valign="top" rowspan="1" colspan="1">Medicine review at hospital discharge or in the posthospital discharge period</td><td align="left" valign="top" rowspan="1" colspan="1">Medicine review in ICU or in hospital only</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study design</td><td align="left" valign="top" rowspan="1" colspan="1">Randomised, quasi-experimental (parallel control group trials and pre/postintervention trials) observational</td><td align="left" valign="top" rowspan="1" colspan="1">Case reports, reviews, editorials, quality improvement studies with interventions, theses or other commentaries</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><p>ICU, intensive care unit; N/A, not available; PICO, participant, intervention, comparison and outcomes.</p></fn></table-wrap-foot></table-wrap><p>We included articles which met the following criteria: involving adults (admitted to an adult critical care environment) and including medicine management data at hospital discharge or following hospital discharge. Thus, we excluded studies which examined transitions of care in the hospital environment, or those which reported in-hospital medicine management in isolation. We also excluded studies which were not peer reviewed, were non-English language, included quality improvement interventions or were in abstract format only.</p><p>Each citation was independently reviewed for eligibility by two clinicians via a review of title and abstract, and then, where appropriate, full-text articles. All extracted papers also had their reference list hand-searched to ensure that all relevant papers had been included. AS, JM, SM, MA and PM undertook this process. Disagreement was resolved via regular meetings of this study team.</p></sec><sec id="s2-3"><title>Quality assessment</title><p>Cohort study quality was assessed using the Newcastle Ottowa Score checklist.<xref rid="R11" ref-type="bibr">11</xref> This consists of the three main domains to assess the quality and risk of bias. These are: patient selection (cohort data source, representativeness and ascertainment of exposure to the outcome of interest), comparability of cohort and outcome assessment (including adequate follow-up time, acquisition of outcome and adequacy of follow-up). Data on risk of bias and the overall quality assessment can be found in <xref rid="SP2" ref-type="supplementary-material">online supplemental file S2</xref>.</p><supplementary-material id="SP2" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/ejhpharm-2023-003715.supp2</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS2" xlink:href="ejhpharm-2023-003715supp002.pdf" content-type="local-data"/>
</p></supplementary-material></sec><sec id="s2-4"><title>Data extraction</title><p>Data were extracted by four clinicians (AS, JM, SM and PM) and entered into a standardised template. All data were cross-checked by a second reviewer. Any discrepancies were resolved by consensus. Data extracted included author, date, location, study design, population, number of patients studied, gender, age, time of follow-up, type of medicine reviewed and main study outcomes. Outcomes were chosen a priori, and the template was piloted before implementation.</p><p>Studies included in this review often examined different classes of medicines. For example, some examined analgesics and others cardiovascular drug management. We placed no restrictions on the type of drug examined as we were interested in obtaining a global view of medicine management.</p></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><sec id="s3-1"><title>Study selection</title><p>The database search initially retrieved 1180 studies; following the removal of duplicates, 1032 unique studies were identified for title and abstract review. A total of 938 studies were excluded as they did not meet the study inclusion criteria, leaving 94 full-text articles for review; 47 studies were then excluded during the full-text review, resulting in 45 papers meeting review inclusion (<xref rid="F1" ref-type="fig">figure 1</xref>). Of note, two papers had the same population for analysis. However, both analyses examined different elements of care which were of interest, and so both were included.<xref rid="R12" ref-type="bibr">12 13</xref>
</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA flowchart.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ejhpharm-2023-003715f01.jpg"/></fig></sec><sec id="s3-2"><title>Summary of studies</title><p>Studies varied widely in their size, scope and methodology. Across the 47 included studies: 28 (60%) were from the USA, six (13%) from Canada, five (11%) from the UK, two (4%) from Australia and one (2%) each from Brazil, Belgium, Denmark, South Korea, Sweden and Switzerland. In total, 29 studies (62%) described medicine management at hospital discharge, and the remaining 18 studies (38%) examined medicine management in the posthospital discharge period. The full characteristics of included studies are presented in the <xref rid="SP3 SP4 SP5 SP6 SP7" ref-type="supplementary-material">online supplemental file S3</xref>. A summary of the main features of the research included is presented in <xref rid="T2" ref-type="table">table 2</xref>. Due to the heterogeneity of the study outcomes and the data captured, we were unable to undertake a meta-analysis.</p><supplementary-material id="SP3" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/ejhpharm-2023-003715.supp3</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS3" xlink:href="ejhpharm-2023-003715supp003.pdf" content-type="local-data"/>
</p></supplementary-material><supplementary-material id="SP4" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/ejhpharm-2023-003715.supp4</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS4" xlink:href="ejhpharm-2023-003715supp004.pdf" content-type="local-data"/>
</p></supplementary-material><supplementary-material id="SP5" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/ejhpharm-2023-003715.supp5</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS5" xlink:href="ejhpharm-2023-003715supp005.pdf" content-type="local-data"/>
</p></supplementary-material><supplementary-material id="SP6" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/ejhpharm-2023-003715.supp6</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS6" xlink:href="ejhpharm-2023-003715supp006.pdf" content-type="local-data"/>
</p></supplementary-material><supplementary-material id="SP7" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/ejhpharm-2023-003715.supp7</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS7" xlink:href="ejhpharm-2023-003715supp007.pdf" content-type="local-data"/>
</p></supplementary-material><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Overview of studies included in this review</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Study characteristic (n=47)</td><td align="left" valign="bottom" rowspan="1" colspan="1">N (%)</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Geographical region</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Australia</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Belgium</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Canada</td><td align="left" valign="top" rowspan="1" colspan="1">6 (13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Denmark</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;South Korea</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Sweden</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Switzerland</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;UK</td><td align="left" valign="top" rowspan="1" colspan="1">5 (11)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;USA</td><td align="left" valign="top" rowspan="1" colspan="1">28 (60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study type</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Retrospective observational cohort</td><td align="left" valign="top" rowspan="1" colspan="1">40 (85)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Prospective observational cohort</td><td align="left" valign="top" rowspan="1" colspan="1">7 (15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study scope</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Multicentre</td><td align="left" valign="top" rowspan="1" colspan="1">12 (26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Single centre</td><td align="left" valign="top" rowspan="1" colspan="1">35 (74)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study population focus</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Mixed (general/mixed medical and surgical specialties)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (62)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Medical ICU (MICU)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cardiac ICU (CICU)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Trauma/surgical/neurosurgical ICU</td><td align="left" valign="top" rowspan="1" colspan="1">4 (9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Elderly patient/chronic medications</td><td align="left" valign="top" rowspan="1" colspan="1">5 (11)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cancer centre general ICU</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Acute kidney injury/renal replacement need</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication type studied*</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Opiates/analgesics</td><td align="left" valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Gastroprotection/acid suppressants</td><td align="left" valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Psychotropic</td><td align="left" valign="top" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Medication changes/PIMs/AIMs</td><td align="left" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cardiovascular</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Main timepoint examined</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hospital discharge</td><td align="left" valign="top" rowspan="1" colspan="1">29 (62)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hospital discharge and post-discharge follow-up</td><td align="left" valign="top" rowspan="1" colspan="1">5 (11)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Outpatient follow-up &lt;6&#8201;months</td><td align="left" valign="top" rowspan="1" colspan="1">8 (17)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Outpatient follow-up &gt;6 to &lt;9&#8201;months</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Outpatient follow-up to &gt;9&#8201;months to 1&#8201;year</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Outpatient follow-up &gt;1&#8201;year</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Source of study data</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Clinical record including discharge prescription/summary</td><td align="left" valign="top" rowspan="1" colspan="1">32 (68)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Face-to-face interview</td><td align="left" valign="top" rowspan="1" colspan="1">7 (15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;National databases</td><td align="left" valign="top" rowspan="1" colspan="1">8 (17)</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><p>*n=53&#8201;as some papers studied more than one medication class.</p></fn><fn id="T2_FN2"><p>AIM, actually inappropriate medication; ICU, intensive care unit; PIM, potentially inappropriate medication.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3"><title>Risk of bias</title><p>The quality assessment for the included studies is shown in <xref rid="SP2" ref-type="supplementary-material">online supplemental file S2</xref>. The overall quality of the studies varied. Across all 47 studies included, the median (IQR) Newcastle Ottawa score was 7 (5&#8211;8) for the studies included.</p></sec><sec id="s3-4"><title>Medication-related problems</title><sec id="s3-4-1"><title>Overview of included studies</title><p>Eleven studies described medication-related problems in critical care survivors<xref rid="R5" ref-type="bibr">5 12&#8211;21</xref> (<xref rid="SP3" ref-type="supplementary-material">online supplemental file S3, table 1</xref>). Two papers examined medication-related problems in the same population of older ICU survivors in the US.<xref rid="R12" ref-type="bibr">12 13</xref> Both studies were included as they focused on different elements of care. Across the studies there was a wide range of definitions and classifications used to define medication-related problems (<xref rid="T3" ref-type="table">table 3</xref>). Four studies examined medication-related problems at hospital discharge,<xref rid="R12" ref-type="bibr">12 13 15 18</xref> and the remaining seven studies examined medication-related problems within the ICU follow-up setting.<xref rid="R5" ref-type="bibr">5 14 16 17 19&#8211;21</xref> One study specifically examined the outcomes of patients admitted to critical care for COVID-19.<xref rid="R20" ref-type="bibr">20</xref>
</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Terminology and definition of medication-related problems used across included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Terminology to define a medication-related problem</td><td align="left" valign="bottom" rowspan="1" colspan="1">Definition</td><td align="left" valign="bottom" rowspan="1" colspan="1">Study</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Inappropriate medication Discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">Unintentional discontinuation of chronic medications<break/>(eg, a statin or antiplatelet/anticoagulant)</td><td align="left" valign="top" rowspan="1" colspan="1">Bell <italic toggle="yes">et al</italic> (2006)<xref rid="R22" ref-type="bibr">22</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Discrepancy: the need for a pharmacy intervention</td><td align="left" valign="top" rowspan="1" colspan="1">Interventions included dose adjustments, additional therapy, inappropriate therapy discontinued and patient/family counselling</td><td align="left" valign="top" rowspan="1" colspan="1">Bottom-Tanzer <italic toggle="yes">et al</italic> (2020)<xref rid="R16" ref-type="bibr">16</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMs<break/>AIMs</td><td align="left" valign="top" rowspan="1" colspan="1">Beer criteria<xref rid="R63" ref-type="bibr">63</xref>
<break/>For example, stress ulcer prophylaxis which should have been discontinued at ICU/hospital discharge</td><td align="left" valign="top" rowspan="1" colspan="1">Morandi <italic toggle="yes">et al</italic> (2011)<xref rid="R12" ref-type="bibr">12</xref>
<break/>Morandi <italic toggle="yes">et al</italic> (2013)<xref rid="R13" ref-type="bibr">13</xref>
<break/>Galli <italic toggle="yes">et al</italic> 2016<xref rid="R18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication-related problem</td><td align="left" valign="top" rowspan="1" colspan="1">Included drug omissions, drug adjustments, duration of treatment advice; patient education and counselling (eg, re-titration of preadmission gabapentin for neuropathic pain)</td><td align="left" valign="top" rowspan="1" colspan="1">MacTavish <italic toggle="yes">et al</italic> (2019)<xref rid="R5" ref-type="bibr">5</xref>
<break/>MacTavish <italic toggle="yes">et al</italic> (2020)<xref rid="R19" ref-type="bibr">19</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pharmacist intervention</td><td align="left" valign="top" rowspan="1" colspan="1">Included drug omissions, drug adjustments, adverse drug event identified or prevented, duration of treatment advice; patient education and counselling (eg, identification of adverse drug events such as hypoglycaemia)</td><td align="left" valign="top" rowspan="1" colspan="1">Stollings <italic toggle="yes">et al</italic> (2018)<xref rid="R21" ref-type="bibr">21</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pharmacist intervention</td><td align="left" valign="top" rowspan="1" colspan="1">Included GDMT optimisation, refill assistance, medication cost assistance, pill box provision, lab monitoring, medication cessation, medication addition and medication dose adjustment (eg, GDMT optimisation of heart failure drug treatment)</td><td align="left" valign="top" rowspan="1" colspan="1">Adie <italic toggle="yes">et al</italic> (2021)<xref rid="R14" ref-type="bibr">14</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication changes</td><td align="left" valign="top" rowspan="1" colspan="1">Classified as appropriate or inappropriate based on discussion with clinical team, patient and ongoing clinical indication (eg, inappropriate continuation of anticoagulants)</td><td align="left" valign="top" rowspan="1" colspan="1">MacTavish <italic toggle="yes">et al</italic> (2021)<xref rid="R20" ref-type="bibr">20</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Potential medication errors and medicine-related problem</td><td align="left" valign="top" rowspan="1" colspan="1">Included Inappropriate discontinuation of chronic medications, difficulties obtaining supplies, administration, information and understanding of the suitability of prescriptions (eg, inappropriate continuation of sedatives at hospital discharge)</td><td align="left" valign="top" rowspan="1" colspan="1">Eijsbroek <italic toggle="yes">et al</italic> (2013)<xref rid="R17" ref-type="bibr">17</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><p>AIM, actually inappropriate medication; GDMT, guideline-directed medical therapy; ICU, intensive care unit; PIM, potentially inappropriate medication.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-4-2"><title>Observations</title><p>There was variation in the number of patients impacted by medication-related problems. For example, a multicentre Canadian study of 834 patients reported that a third of patients were impacted by a medication-related problem at hospital discharge,<xref rid="R15" ref-type="bibr">15</xref> whereas in in a single centre study of older adults in the US, 85% of patients experienced a medication-related problem (defined as a potentially inappropriate medication).<xref rid="R13" ref-type="bibr">13</xref> In the ICU follow-up setting, 62.80&#8211;100% of patients who attended experienced a medication-related problem or required a pharmacy intervention.<xref rid="R5" ref-type="bibr">5 14 19 21</xref> These medication-related problems were classified as clinically significant in 86.40% of medication-related problems examined in one study, and 64% in a further single centre study.<xref rid="R5" ref-type="bibr">5 19</xref>
</p><p>The studies varied in the types of drugs involved in medication-related problems. One study examined the proportion of patients unintentionally discharged from hospital with chronic medication omitted and found that approximately one-third of patients experienced problems with their chronic disease management medication.<xref rid="R15" ref-type="bibr">15</xref> A further study undertaken in the ICU follow-up setting found that 5.30% of patients did not have medications for chronic conditions restarted following discharge from hospital.<xref rid="R17" ref-type="bibr">17</xref> Two studies, one at hospital discharge and one based in the ICU follow-up setting, found that analgesics including opiates were the most likely medications to be involved in medication-related problems.<xref rid="R5" ref-type="bibr">5 12</xref>
</p></sec><sec id="s3-4-3"><title>Risk factors</title><p>Risk factors for medication-related problems at hospital discharge included the omission of medications at ICU discharge,<xref rid="R15" ref-type="bibr">15</xref> not being discharged home<xref rid="R12" ref-type="bibr">12</xref> and discharge from a surgical service.<xref rid="R12" ref-type="bibr">12</xref> Risk factors for medication-related problems in the ICU follow-up setting included hospital length of stay, and the number of ICU discharge medications and analgesic requirements at ICU discharge and at the clinic attendance.<xref rid="R5" ref-type="bibr">5 19</xref>
</p></sec></sec><sec id="s3-5"><title>Gastrointestinal protection medications</title><sec id="s3-5-1"><title>Overview of included studies</title><p>There were 12 studies which examined the use of gastrointestinal protection agents in the hospital discharge period (<xref rid="SP4" ref-type="supplementary-material">online supplemental file S3, table 2</xref>).<xref rid="R17" ref-type="bibr">17 22&#8211;32</xref> This drug group includes proton pump inhibitors (PPI), H2 receptor antagonists and Sucralfate. Ten studies examined gastrointestinal protection use at hospital discharge,<xref rid="R23" ref-type="bibr">23&#8211;32</xref> one examined dispensing of gastric acid suppressors up to 90 days following discharge<xref rid="R22" ref-type="bibr">22</xref> and three studies examined gastrointestinal protection in the outpatient follow-up setting.<xref rid="R17" ref-type="bibr">17 29 30</xref>
</p></sec><sec id="s3-5-2"><title>Observations</title><p>The number of inappropriate gastrointestinal protection agent prescriptions reported at hospital discharge ranged considerably across the studies included. For example, in three studies, all gastrointestinal protection agents prescribed at hospital discharge were deemed to be prescribed inappropriately.<xref rid="R23" ref-type="bibr">23 30 32</xref> In contrast, a single centre study from the US found that only 15.7% of prescriptions at hospital discharge were inappropriate.<xref rid="R27" ref-type="bibr">27</xref> Three studies examined inappropriate continuation of these drugs beyond hospital discharge.<xref rid="R23" ref-type="bibr">23 29 30</xref> In the first, 58.20% of patients prescribed gastrointestinal protection at 3&#8201;months were prescribed them inappropriately.<xref rid="R30" ref-type="bibr">30</xref> The second study, which examined gastrointestinal protection at a 4-week telephone follow-up call, found that only 5% of patients prescribed gastrointestinal protection had a compelling reason for continuation.<xref rid="R29" ref-type="bibr">29</xref> In the most recent study, 64% of patients remained on proton pump inhibitors with no indication following hospital discharge.<xref rid="R23" ref-type="bibr">23</xref> Conversely, three studies highlighted that up to 15.40% of patients were not restarted on previously prescribed (prehospital) gastrointestinal protection at hospital discharge.<xref rid="R22" ref-type="bibr">22 24 30</xref>
</p></sec><sec id="s3-5-3"><title>Risk factors</title><p>Several risk factors for continued use of gastrointestinal protection medications were identified across three studies. Risk factors included discharge to a long-term care facility, an ICU admission a surgical (as opposed to medical) admission and mechanical ventilation.<xref rid="R22" ref-type="bibr">22 23 25</xref>
</p></sec></sec><sec id="s3-6"><title>Psychotropic medications</title><sec id="s3-6-1"><title>Overview of included studies</title><p>Fourteen studies examined the use of psychotropic medications in survivors of critical care (<xref rid="SP5" ref-type="supplementary-material">online supplemental file S3, table 3</xref>).<xref rid="R33" ref-type="bibr">33&#8211;46</xref> Drugs included were antipsychotic and anxiolytic agents alongside antidepressants. Twelve studies examined psychotropic medications use in critical care survivors at hospital discharge;<xref rid="R34" ref-type="bibr">34&#8211;45</xref> one study examined their use up to 180 days following hospital discharge<xref rid="R33" ref-type="bibr">33</xref> and the final study examined the use of these medications up to 1&#8201;year posthospital discharge.<xref rid="R46" ref-type="bibr">46</xref>
</p></sec><sec id="s3-6-2"><title>Observations</title><p>Across the studies, in those patients prescribed psychotropic medications during admission, there was wide variation in the continued use of these drugs at hospital discharge (range 10.30&#8211;61%), although the appropriateness of this continued use was difficult to assess across the studies.<xref rid="R34" ref-type="bibr">34&#8211;45</xref> Four studies gave details on the prescription appropriateness at hospital discharge; one single centre US study found 54 of their cohort of 161 patients (34%) had been continued on antipsychotics or anxiolytics at hospital discharge, with no patient having a documented reason for their use.<xref rid="R37" ref-type="bibr">37</xref> In another single site study, 68.40% of patients prescribed atypical antipsychotics at hospital discharge had no ongoing indication for their use,<xref rid="R39" ref-type="bibr">39</xref> while a further study found that 24.40% of survivors treated with antipsychotics during critical illness, remined on these medicine at hospital discharge, despite two-thirds of these survivors having normal mental status documented.<xref rid="R45" ref-type="bibr">45</xref> Finally, a single centre cohort study based in a trauma and neurosurgical unit found that 67.10% of prescriptions, the majority of which were for quetiapine, were inappropriate at hospital discharge.<xref rid="R44" ref-type="bibr">44</xref>
</p></sec><sec id="s3-6-3"><title>Risk factors</title><p>One large Danish registry study examined the use of antipsychotics in mechanically ventilated patients, in comparison with a hospitalised and a general population cohort, up to 1&#8201;year posthospital discharge. In this study, they found that in those who had received mechanical ventilation, the risk of new psychoactive medication prescriptions increased in the first 3&#8201;months following hospital discharge in comparison with the hospital and general control population, although these differences had largely resolved by 12&#8201;months.<xref rid="R46" ref-type="bibr">46</xref> Another VA registry study in the US also found that patients with a diagnosis of sepsis were more likely to be continued on antipsychotics in the posthospital discharge phase (up to 180 days).<xref rid="R45" ref-type="bibr">45</xref> Seven studies found critical illness specific variables, such as ICU length of stay, severity of illness and the type of admission were risk factors for the continuation of psychotropic medications.<xref rid="R34" ref-type="bibr">34 35 38 40&#8211;42 44</xref>
</p></sec></sec><sec id="s3-7"><title>Analgesia</title><sec id="s3-7-1"><title>Overview of included studies</title><p>In total, 12 studies examined the use of analgesics in the posthospital discharge period (<xref rid="SP6" ref-type="supplementary-material">online supplemental file S3, table 4</xref>).<xref rid="R5" ref-type="bibr">5 17 20 47&#8211;55</xref> Analgesics examined included simple analgesics such as paracetamol alongside weak and strong opioids. Five studies examined the use of analgesia at hospital discharge,<xref rid="R47" ref-type="bibr">47 48 50 52 55</xref> three studies were based in the ICU follow-up setting<xref rid="R5" ref-type="bibr">5 17 20</xref> and six studies examined analgesics longitudinally across the critical care recovery period (up to 24&#8201;months following discharge.<xref rid="R48" ref-type="bibr">48 49 51 53&#8211;55</xref> Studies varied in their inclusion definition, with some studies examining chronic opioid use, some examining the outcomes of opioid na&#239;ve patients and others examining analgesics in all ICU survivors.</p></sec><sec id="s3-7-2"><title>Observations</title><p>New analgesic prescribing was reported in 10 studies.<xref rid="R5" ref-type="bibr">5 17 20 47 48 50&#8211;52 54 55</xref> Five studies reported new analgesia prescriptions at hospital discharge (number of patients receiving new analgesics at hospital discharge (range 31.80&#8211;47.10%).<xref rid="R47" ref-type="bibr">47 48 50 52 55</xref> Three studies were set in the ICU follow-up setting, and two of the studies took place with the general ICU population and reported new analgesia requirements in 27% and 76% of patients included.<xref rid="R5" ref-type="bibr">5 17</xref> In one of these studies, 16% of the total patient cohort (183 patients) were receiving new opiate prescriptions in the post-ICU recovery phase.<xref rid="R5" ref-type="bibr">5</xref> A further study, also in the ICU follow-up setting, specifically examined new analgesic requirements in critically ill COVID-19 survivors and found a significant increase in the number of patients taking regular analgesia following severe COVID-19 infection.<xref rid="R20" ref-type="bibr">20</xref> The final study which reported increased analgesic use, demonstrated that 20% of patients filled new opiate prescriptions within 7&#8201;days of hospital discharge; however, persistent opiate use at 1&#8201;year fell to between 2.60&#8211;4.90%.</p><p>Conversely, a large population-based cohort study of elderly ICU survivors with chronic opioid use found relatively static opioid use in the posthospital discharge period (up to 180 days posthospital discharge), with 22% of patients on a higher dose of opiate compared with prehospitalisation, 19.80% receiving the same dose, and 21.50% of patients receiving a lower dose.<xref rid="R49" ref-type="bibr">49</xref>
</p></sec><sec id="s3-7-3"><title>Risk factors</title><p>Nine studies reported risk factors for continuation of analgesics.<xref rid="R47" ref-type="bibr">47&#8211;52 54 55</xref> Risk factors included a cardiac critical care and surgical admissions, a history of illicit drug use (including alcohol and substance use disorders), intubation, younger age, a diagnosis of sepsis, previous benzodiazepine use, chronic opiate use preadmission, a higher cumulative dose of opiate in the ICU and an ICU admission diagnosis of malignancy.</p></sec></sec><sec id="s3-8"><title>Cardiac medications</title><sec id="s3-8-1"><title>Overview of included studies</title><p>In total, four studies examined cardiac medication management in survivors of critical care (<xref rid="SP7" ref-type="supplementary-material">online supplemental file S3, table 5</xref>).<xref rid="R22" ref-type="bibr">22 33 56 57</xref> Two studies examined cardiac medication use at hospital discharge<xref rid="R56" ref-type="bibr">56 57</xref> and two studies examined their use following hospital discharge.<xref rid="R22" ref-type="bibr">22 33</xref>
</p></sec><sec id="s3-8-2"><title>Observations</title><p>One study found that 34% of patients were continued on midodrine at hospital discharge, with an estimated 50% of these prescriptions deemed inappropriate.<xref rid="R57" ref-type="bibr">57</xref> In the two studies which examined cardiac medications in the posthospital discharge period, between 15.10&#8211;22.80% of critical care and sepsis survivors did not have chronic cardiac medications such as statins and antiplatelets restarted or refilled.<xref rid="R22" ref-type="bibr">22 33</xref>
</p></sec><sec id="s3-8-3"><title>Risk factors</title><p>An ICU admission and a diagnosis of sepsis were risk factors for unintentional discontinuation of chronic cardiac medications.<xref rid="R22" ref-type="bibr">22 33</xref>
</p></sec></sec></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>This systematic review aimed to understand changes to medication management and medication problems in critical care survivors during the hospital discharge period. It has found that as many as 80% of critical care survivors can experience problems with medication management during recovery.<xref rid="R13" ref-type="bibr">13 19</xref> This included unintentional discontinuation of chronic disease medications in up to a quarter of patients; conversely, we also found that many patients were continued, often inappropriately, on acutely prescribed drugs. Problems occurred across multiple classes of drugs, including gastrointestinal protection, psychotropic, analgesic and cardiac medications. Several risk factors for medication-related problems emerged including the need for mechanical ventilation, a sepsis diagnosis and a critical care admission (vs hospital admission only).</p><p>It is well recognised that pharmacists play a key role within the ICU setting. However, at present their role in recovery programmes is sporadic, and has not been integrated into national recommendations. For example, the UK Faculty of Intensive Care Medicine&#8217;s Guidelines for the provision of intensive care services makes no mention of the pharmacist in the delivery of ICU after care.<xref rid="R58" ref-type="bibr">58</xref> The findings of this review would suggest that the role of the pharmacist within recovery programmes and across the recovery timeline more broadly may improve outcomes for patients, and potentially provide benefits to the healthcare system. More work in this area is required.</p><p>This review found inconsistent results in relation to pain management and opiate use in the posthospital discharge period. Studies demonstrated both relatively static use, as well as significant increases in opiate prescribing,<xref rid="R20" ref-type="bibr">20 51</xref> although synthesis of these data was hindered by the heterogeneity of the inclusion criteria across studies. It is important to recognise that no study matched medication management and medication-related problems with patient reported outcomes, such as global quality of life or pain scores. We do not know if patients were discontinued opiates with the addition of subsequent substitutes, or if these drugs were inappropriately prescribed. Recent evidence has demonstrated chronic pain occurs in up to two-thirds of ICU survivors; as such, future research should link patient-reported outcomes (eg, pain scores with medicine management), thus ensuring a holistic picture of the challenges which patients face following hospital discharge.<xref rid="R59" ref-type="bibr">59 60</xref>
</p><p>We were unable to undertake a meta-analysis with these data owing to the heterogenous nature of the research available. Studies varied in the definition of medication-related problems and examined these issues across various timeframes. Given this, future work should examine which outcomes are important to gather and the timeframe which is most appropriate. This step would allow data to be fully synthesised and relevant recommendations for practice to be established.</p><p>There are limitations to this review. First, we were unable to examine patient-level factors which could have contributed to the medication-related problems described across transitions of care. Socioeconomic factors such as educational attainment and access to adequate financial support are known to influence recovery from critical illness.<xref rid="R61" ref-type="bibr">61 62</xref> These social factors may have influenced issues such as medication-related problems and access to drugs within specific healthcare systems. Future work should examine patient demographics, alongside healthcare access following discharge, to understand any individual risk factors. Second, many of the studies included used large-scale national databases to examine outcomes. These databases have inherent problems; most notably in this review, the inability to understand why medicines may have been stopped or started. Third, there was a wide range of cohort sizes included in this review. There was also significant variation in the timepoint of measure, the type of measure and the setting in which the measure was undertaken. The event rate of medication errors was also inconsistently reported; having this event rate would have allowed an enhanced understanding of the interaction between the sample size and the outcomes described. This variation makes it challenging to compare studies and synthesise them accurately. Future work should endeavour to create a standardised approach to outcome measurement in this field.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>Following critical illness, patients can experience problems and changes to medicines. These changes are present across multiple health systems and classes of medications. Further research is required to understand optimal medicine management across the full recovery trajectory of critical illness.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Contributors:</bold> JM conceptualisation of the study AS and SM conducted the formal searches JM, AS, MA and PM conducted the analysis (formal analysis) JM, AS, PM and SM contributed to the interpretation of the findings (validation). All authors critically revised the paper for intellectual content and approved the final version of the manuscript.</p></fn><fn fn-type="other"><p><bold>Funding:</bold> JM is funded by a The Healthcare Improvement Studies Institute (University of Cambridge) Fellowship PD-2019-02-16. AL is funded by the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17).</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn></fn-group><sec sec-type="data-availability"><title>Data availability statement</title><p>All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to the study is included in the article or uploaded as supplementary information.</p></sec><sec sec-type="ethics-statement"><title>Ethics statements</title><sec><title>Patient consent for publication</title><p content-type="ethics-consent-to-publish">Not applicable.</p></sec><sec><title>Ethics approval</title><p content-type="ethics-approval">Not applicable.</p></sec></sec><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Flanders</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Transitions of care</article-title>. <source>Ann Intern Med</source><year>2013</year>;<volume>158</volume>(<issue>5_Part_1</issue>):<elocation-id>ITC3</elocation-id>. <pub-id pub-id-type="doi">10.7326/0003-4819-158-5-201303050-01003</pub-id><pub-id pub-id-type="pmid">23460071</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sutton</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dixon-Woods</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tarrant</surname><given-names>C</given-names></string-name></person-group>. <article-title>Ethnographic process evaluation of a quality improvement project to improve transitions of care for older people</article-title>. <source>BMJ Open</source><year>2016</year>;<volume>6</volume>:<elocation-id>e010988</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2015-010988</pub-id><pub-id pub-id-type="pmcid">PMC4985971</pub-id><pub-id pub-id-type="pmid">27491666</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haines</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Hibbert</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Leggett</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Transitions of care after critical illness-challenges to recovery and adaptive problem solving</article-title>. <source>Crit Care Med</source><year>2021</year>;<volume>49</volume>:<fpage>1923</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000005095</pub-id><pub-id pub-id-type="pmid">34091486</pub-id><pub-id pub-id-type="pmcid">PMC8516700</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwan</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sampson</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Medication reconciliation during transitions of care as a patient safety strategy: a systematic review</article-title>. <source>Ann Intern Med</source><year>2013</year>;<volume>158</volume>(<issue>5 Pt 2</issue>):<fpage>397</fpage>&#8211;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-158-5-201303051-00006</pub-id><pub-id pub-id-type="pmid">23460096</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>MacTavish</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Quasim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Purdie</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Medication-Related problems in intensive care unit survivors: learning from a multicenter program</article-title>. <source>Ann Am Thorac Soc</source><year>2020</year>;<volume>17</volume>:<fpage>1326</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.202005-444RL</pub-id><pub-id pub-id-type="pmid">32716636</pub-id><pub-id pub-id-type="pmcid">PMC7640628</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Redmond</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Grimes</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>McDonnell</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of medication reconciliation for improving transitions of care</article-title>. <source>Cochrane Database Syst Rev</source><year>2018</year>;<volume>8</volume>:<elocation-id>CD010791</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD010791.pub2</pub-id><pub-id pub-id-type="pmid">30136718</pub-id><pub-id pub-id-type="pmcid">PMC6513651</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dennis</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>McGovern</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Vollmer</surname><given-names>SJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Improving survival of critical care patients with coronavirus disease 2019 in England: a national cohort study, March to June 2020</article-title>. <source>Crit Care Med</source><year>2021</year>;<volume>49</volume>:<fpage>209</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000004747</pub-id><pub-id pub-id-type="pmid">33105150</pub-id><pub-id pub-id-type="pmcid">PMC7803441</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bourne</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Jennings</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Panagioti</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Medication-Related interventions to improve medication safety and patient outcomes on transition from adult intensive care settings: a systematic review and meta-analysis</article-title>. <source>BMJ Qual Saf</source><year>2022</year>;<volume>31</volume>:<fpage>609</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1136/bmjqs-2021-013760</pub-id><pub-id pub-id-type="pmcid">PMC9304084</pub-id><pub-id pub-id-type="pmid">35042765</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Institute of Medicine Committee on Quality of Health Care in A</collab></person-group>. <source>To Err is Human: Building a Safer Health System</source>. <publisher-loc>Washington (DC)</publisher-loc>: <publisher-name>National Academies Press (US) Copyright 2000 by the National Academy of Sciences. All rights reserved</publisher-name>, <year>2000</year>.</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Azoulay</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>De Waele</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ferrer</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Symptoms of burnout in intensive care unit specialists facing the COVID-19 outbreak</article-title>. <source>Ann Intensive Care</source><year>2020</year>;<volume>10</volume>:<elocation-id>110</elocation-id>. <pub-id pub-id-type="doi">10.1186/s13613-020-00722-3</pub-id><pub-id pub-id-type="pmid">32770449</pub-id><pub-id pub-id-type="pmcid">PMC7414284</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Wells</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connell</surname><given-names>B</given-names></string-name></person-group>. <source>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses</source>. <publisher-name>The Ottowa Hospital Research Institute</publisher-name>, <year>2009</year>.</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morandi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vasilevskis</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pandharipande</surname><given-names>PP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Inappropriate medication prescriptions in elderly adults surviving an intensive care unit hospitalization</article-title>. <source>J Am Geriatr Soc</source><year>2013</year>;<volume>61</volume>:<fpage>1128</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.12329</pub-id><comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://onlinelibrary.wiley.com/toc/15325415/61/7">https://onlinelibrary.wiley.com/toc/15325415/61/7</uri><pub-id pub-id-type="pmid">23855843</pub-id><pub-id pub-id-type="pmcid">PMC3713508</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morandi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vasilevskis</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Pandharipande</surname><given-names>PP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Inappropriate medications in elderly ICU survivors: where to intervene?</article-title><source>Arch Intern Med</source><year>2011</year>;<volume>171</volume>:<fpage>1032</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1001/archinternmed.2011.233</pub-id><pub-id pub-id-type="pmid">21670372</pub-id><pub-id pub-id-type="pmcid">PMC3575737</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adie</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Konerman</surname><given-names>MC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of a pharmacist in an interdisciplinary post-cardiac intensive care unit clinic</article-title>. <source>Heart Lung</source><year>2022</year>;<volume>52</volume>:<fpage>48</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrtlng.2021.11.010</pub-id><pub-id pub-id-type="pmid">34872013</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bell</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Rahimi-Darabad</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Orner</surname><given-names>AI</given-names></string-name></person-group>. <article-title>Discontinuity of chronic medications in patients discharged from the intensive care unit</article-title>. <source>J Gen Intern Med</source><year>2006</year>;<volume>21</volume>:<fpage>937</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1525-1497.2006.00499.x</pub-id><pub-id pub-id-type="pmid">16918738</pub-id><pub-id pub-id-type="pmcid">PMC1831608</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bottom-Tanzer</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Poyant</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Louzada</surname><given-names>MT</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>High occurrence of postintensive care syndrome identified in surgical ICU survivors after implementation of a multidisciplinary clinic</article-title>. <source>J Trauma Acute Care Surg</source><year>2021</year>;<volume>91</volume>:<fpage>406</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1097/TA.0000000000003231</pub-id><pub-id pub-id-type="pmid">34108416</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eijsbroek</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>DCJ</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Medication issues experienced by patients and carers after discharge from the intensive care unit</article-title>. <source>J Crit Care</source><year>2013</year>;<volume>28</volume>:<fpage>46</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2012.06.002</pub-id><pub-id pub-id-type="pmid">22835420</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galli</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Reis</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Andrzejevski</surname><given-names>VM</given-names></string-name></person-group>. <article-title>Potentially inappropriate prescribing andthe risk of adverse drug reactions in critically ill older adults</article-title>. <source>Pharm Pract (Granada)</source><year>2016</year>;<volume>14</volume>:<fpage>818</fpage>. <pub-id pub-id-type="doi">10.18549/PharmPract.2016.04.818</pub-id><pub-id pub-id-type="pmid">28042352</pub-id><pub-id pub-id-type="pmcid">PMC5184374</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>MacTavish</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Quasim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of a pharmacist intervention at an intensive care rehabilitation clinic</article-title>. <source>BMJ Open Qual</source><year>2019</year>;<volume>8</volume>:<elocation-id>e000580</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjoq-2018-000580</pub-id><pub-id pub-id-type="pmcid">PMC6768365</pub-id><pub-id pub-id-type="pmid">31637320</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>MacTavish</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>McPeake</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Breslin</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluation of medication changes following severe COVID-19 infection: a multicentre evaluation</article-title>. <source>BMJ Open Resp Res</source><year>2021</year>;<volume>8</volume>:<elocation-id>e001037</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjresp-2021-001037</pub-id><pub-id pub-id-type="pmcid">PMC8650475</pub-id><pub-id pub-id-type="pmid">34872966</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stollings</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Bloom</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Sevin</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Reply: critical care pharmacists and medication management in an ICU recovery center</article-title>. <source>Ann Pharmacother</source><year>2019</year>;<volume>53</volume>:<elocation-id>106</elocation-id>. <pub-id pub-id-type="doi">10.1177/1060028018799501</pub-id><pub-id pub-id-type="pmid">30175590</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bell</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Brener</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Gunraj</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases</article-title>. <source>JAMA</source><year>2011</year>;<volume>306</volume>:<fpage>840</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2011.1206</pub-id><pub-id pub-id-type="pmid">21862745</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blackett</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Faye</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Phipps</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence and risk factors for inappropriate continuation of proton pump inhibitors after discharge from the intensive care unit</article-title>. <source>Mayo Clin Proc</source><year>2021</year>;<volume>96</volume>:<fpage>2550</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.mayocp.2020.07.038</pub-id><pub-id pub-id-type="pmid">33308869</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farley</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Barned</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Crozier</surname><given-names>TM</given-names></string-name></person-group>. <article-title>Inappropriate continuation of stress ulcer prophylaxis beyond the intensive care setting</article-title>. <source>Crit Care Resusc</source><year>2013</year>;<volume>15</volume>:<fpage>147</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">23961576</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farrell</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Mercogliano</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kuntz</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Overuse of stress ulcer prophylaxis in the critical care setting and beyond</article-title>. <source>J Crit Care</source><year>2010</year>;<volume>25</volume>:<fpage>214</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2009.05.014</pub-id><pub-id pub-id-type="pmid">19683892</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Franchitti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Piubellini</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sadeghipour</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Adequacy of stress ulcer prophylaxis prescription in the intensive care unit: an observational study</article-title>. <source>Swiss Med Wkly</source><year>2020</year>;<volume>150</volume>:<elocation-id>Swiss Med Wkly. 2020;150:w20322</elocation-id>. <pub-id pub-id-type="doi">10.4414/smw.2020.20322</pub-id><pub-id pub-id-type="pmid">32905610</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hatch</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fish</surname><given-names>JT</given-names></string-name></person-group>. <article-title>Stress ulcer prophylaxis: reducing non-indicated prescribing after hospital discharge</article-title>. <source>Ann Pharmacother</source><year>2010</year>;<volume>44</volume>:<fpage>1565</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1P167</pub-id><pub-id pub-id-type="pmid">20841521</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mehta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Martinez Guasch</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kamen</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Proton pump inhibitors in the elderly hospitalized patient: evaluating appropriate use and deprescribing</article-title>. <source>J Pharm Technol</source><year>2020</year>;<volume>36</volume>:<fpage>54</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1177/8755122519894953</pub-id><pub-id pub-id-type="pmid">34752519</pub-id><pub-id pub-id-type="pmcid">PMC7047242</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murphy</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Ferrentino</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit</article-title>. <source>Pharmacotherapy</source><year>2008</year>;<volume>28</volume>:<fpage>968</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1592/phco.28.8.968</pub-id><pub-id pub-id-type="pmid">18657013</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wohlt</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Fish</surname><given-names>JT</given-names></string-name></person-group>. <article-title>Inappropriate continuation of stress ulcer prophylactic therapy after discharge</article-title>. <source>Ann Pharmacother</source><year>2007</year>;<volume>41</volume>:<fpage>1611</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1K227</pub-id><pub-id pub-id-type="pmid">17848420</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Norman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Litton</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Incidence and cost of stress ulcer prophylaxis after discharge from the intensive care unit: a retrospective study</article-title>. <source>Crit Care Resusc</source><year>2016</year>;<volume>18</volume>:<fpage>270</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">27903209</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shin</surname><given-names>S</given-names></string-name></person-group>. <article-title>Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review</article-title>. <source>Ther Clin Risk Manag</source><year>2015</year>;<volume>11</volume>:<fpage>649</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S81759</pub-id><pub-id pub-id-type="pmid">26005351</pub-id><pub-id pub-id-type="pmcid">PMC4420549</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coe</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Vincent</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Iwashyna</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Statin discontinuation and new antipsychotic use after an acute hospital stay vary by hospital</article-title>. <source>PLOS ONE</source><year>2020</year>;<volume>15</volume>:<elocation-id>e0232707</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0232707</pub-id><pub-id pub-id-type="pmid">32384108</pub-id><pub-id pub-id-type="pmcid">PMC7209203</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dixit</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Barbarello Andrews</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Radparvar</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Descriptive analysis of the unwarranted continuation of antipsychotics for the management of ICU delirium during transitions of care: a multicenter evaluation across new Jersey</article-title>. <source>Am J Health Syst Pharm</source><year>2021</year>;<volume>78</volume>:<fpage>1385</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1093/ajhp/zxab180</pub-id><pub-id pub-id-type="pmid">33895793</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farrokh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Castle</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Heavner</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Continuation rate of atypical antipsychotics after discharge when initiated in the intensive care unit</article-title>. <source>J Pharm Pract</source><year>2017</year>;<volume>30</volume>:<fpage>342</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1177/0897190016645026</pub-id><pub-id pub-id-type="pmid">27129913</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flurie</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Gonzales</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Tata</surname><given-names>AL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Hospital delirium treatment: continuation of antipsychotic therapy from the intensive care unit to discharge</article-title>. <source>Am J Health Syst Pharm</source><year>2015</year>;<volume>72</volume>(<issue>23 Suppl 3</issue>):<fpage>S133</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2146/ajhp150474</pub-id><pub-id pub-id-type="pmid">26582298</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gilbert</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Morales</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Searcy</surname><given-names>RJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluation of neuroleptic utilization in the intensive care unit during transitions of care</article-title>. <source>J Intensive Care Med</source><year>2017</year>;<volume>32</volume>:<fpage>158</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1177/0885066615622424</pub-id><pub-id pub-id-type="pmid">28103769</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jasiak</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Middleton</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Camamo</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluation of discontinuation of atypical antipsychotics prescribed for ICU delirium</article-title>. <source>J Pharm Pract</source><year>2013</year>;<volume>26</volume>:<fpage>253</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1177/0897190012465987</pub-id><pub-id pub-id-type="pmid">23184410</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kram</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Kram</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>KR</given-names></string-name></person-group>. <article-title>Implications of atypical antipsychotic prescribing in the intensive care unit</article-title>. <source>J Crit Care</source><year>2015</year>;<volume>30</volume>:<fpage>814</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2015.03.030</pub-id><pub-id pub-id-type="pmid">25887805</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karamchandani</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schoaps</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Bonavia</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Continuation of atypical antipsychotic medications in critically ill patients discharged from the hospital: a single-center retrospective analysis</article-title>. <source>Ther Adv Drug Saf</source><year>2019</year>;<volume>10</volume>:<fpage>2042098618809933</fpage>. <pub-id pub-id-type="doi">10.1177/2042098618809933</pub-id><pub-id pub-id-type="pmid">31019677</pub-id><pub-id pub-id-type="pmcid">PMC6463330</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lambert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vermassen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fierens</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Discharge from hospital with newly administered antipsychotics after intensive care unit delirium-incidence and contributing factors</article-title>. <source>J Crit Care</source><year>2021</year>;<volume>61</volume>:<fpage>162</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2020.10.030</pub-id><pub-id pub-id-type="pmid">33171333</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Levine</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Lemieux</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Aquino</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Risk factors for continuation of atypical antipsychotics at hospital discharge in two intensive care unit cohorts</article-title>. <source>Clinical Medicine Insights: Psychiatry</source><year>2019</year>;<volume>10</volume>:<fpage>117955731986381</fpage>. <pub-id pub-id-type="doi">10.1177/1179557319863813</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marshall</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Herzig</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>MD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Antipsychotic utilization in the intensive care unit and in transitions of care</article-title>. <source>J Crit Care</source><year>2016</year>;<volume>33</volume>:<fpage>119</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2015.12.017</pub-id><pub-id pub-id-type="pmid">26818629</pub-id><pub-id pub-id-type="pmcid">PMC4842336</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rowe</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname><given-names>RA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Risk factors for discharge on a new antipsychotic medication after admission to an intensive care unit</article-title>. <source>J Crit Care</source><year>2015</year>;<volume>30</volume>:<fpage>1283</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2015.08.009</pub-id><pub-id pub-id-type="pmid">26383104</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tomichek</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Stollings</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Pandharipande</surname><given-names>PP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Antipsychotic prescribing patterns during and after critical illness: a prospective cohort study</article-title>. <source>Crit Care</source><year>2016</year>;<volume>20</volume>:<fpage>378</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-016-1557-1</pub-id><pub-id pub-id-type="pmid">27881149</pub-id><pub-id pub-id-type="pmcid">PMC5122157</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wunsch</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Christiansen</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Johansen</surname><given-names>MB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Psychiatric diagnoses and psychoactive medication use among nonsurgical critically ill patients receiving mechanical ventilation</article-title>. <source>JAMA</source><year>2014</year>;<volume>311</volume>:<fpage>1133</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2014.2137</pub-id><pub-id pub-id-type="pmid">24643603</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Academia</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Gabriel</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Mueller</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid prescribing after discharge in a previously mechanically ventilated, opioid-na&#239;ve cohort</article-title>. <source>Ann Pharmacother</source><year>2020</year>;<volume>54</volume>:<fpage>1065</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1177/1060028020919122</pub-id><pub-id pub-id-type="pmid">32349532</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krancevich</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Belfer</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Draper</surname><given-names>HM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of opioid administration in the intensive care unit and subsequent use in opioid-na&#239;ve patients</article-title>. <source>Ann Pharmacother</source><year>2022</year>;<volume>56</volume>:<fpage>52</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1177/10600280211016856</pub-id><pub-id pub-id-type="pmid">33998324</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>HT</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Gomes</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid use after ICU admission among elderly chronic opioid users in Ontario: a population-based cohort study</article-title>. <source>Crit Care Med</source><year>2018</year>;<volume>46</volume>:<fpage>1934</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000003401</pub-id><pub-id pub-id-type="pmid">30222633</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Witcraft</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Gonzales</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Seung</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Continuation of opioid therapy at transitions of care in critically ill patients</article-title>. <source>J Intensive Care Med</source><year>2021</year>;<volume>36</volume>:<fpage>879</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1177/0885066620933798</pub-id><pub-id pub-id-type="pmid">32552281</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wunsch</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>New opioid use after invasive mechanical ventilation and hospital discharge</article-title>. <source>Am J Respir Crit Care Med</source><year>2020</year>;<volume>202</volume>:<fpage>568</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201912-2503OC</pub-id><pub-id pub-id-type="pmid">32348694</pub-id><pub-id pub-id-type="pmcid">PMC7427379</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tollinche</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Seier</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Discharge prescribing of enteral opioids in opioid na&#239;ve patients following non-surgical intensive care: a retrospective cohort study</article-title>. <source>J Crit Care</source><year>2022</year>;<volume>68</volume>:<fpage>16</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2021.10.021</pub-id><pub-id pub-id-type="pmid">34856489</pub-id><pub-id pub-id-type="pmcid">PMC9473333</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>von Oelreich</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Eriksson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sj&#246;lund</surname><given-names>K-F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid use after intensive care: a nationwide cohort study</article-title>. <source>Crit Care Med</source><year>2021</year>;<volume>49</volume>:<fpage>462</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000004896</pub-id><pub-id pub-id-type="pmid">33512940</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karamchandani</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pyati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bryan</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>New persistent opioid use after postoperative intensive care in US veterans</article-title>. <source>JAMA Surg</source><year>2019</year>;<volume>154</volume>:<fpage>778</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1001/jamasurg.2019.0899</pub-id><pub-id pub-id-type="pmid">31166584</pub-id><pub-id pub-id-type="pmcid">PMC6551581</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yaffe</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Green</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>MB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Is admission to the intensive care unit associated with chronic opioid use? A 4-year follow-up of intensive care unit survivors</article-title>. <source>J Intensive Care Med</source><year>2017</year>;<volume>32</volume>:<fpage>429</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1177/0885066615618189</pub-id><pub-id pub-id-type="pmid">26609023</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choon</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Lumlertgul</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Cameron</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Discharge documentation and follow-up of critically ill patients with acute kidney injury treated with kidney replacement therapy: a retrospective cohort study</article-title>. <source>Front Med (Lausanne)</source><year>2021</year>;<volume>8</volume>:<fpage>710228</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2021.710228</pub-id><pub-id pub-id-type="pmid">34595187</pub-id><pub-id pub-id-type="pmcid">PMC8476795</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rizvi</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Nei</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Gajic</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Continuation of newly initiated midodrine therapy after intensive care and hospital discharge: a single-center retrospective study</article-title>. <source>Crit Care Med</source><year>2019</year>;<volume>47</volume>:<fpage>e648</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000003814</pub-id><pub-id pub-id-type="pmid">31107279</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Medicine FoIC</collab></person-group>. <article-title>Guidelines for the provision of intensive cares service</article-title>. <year>2019</year>.</mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Henderson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Quasim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluation of a health and social care programme to improve outcomes following critical illness: a multicentre study</article-title>. <source>Thorax</source><year>2023</year>;<volume>78</volume>:<fpage>160</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2021-218428</pub-id><pub-id pub-id-type="pmid">35314485</pub-id><pub-id pub-id-type="pmcid">PMC9872253</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Devine</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Quasim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McPeake</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Chronic pain in intensive care unit survivors: incidence, characteristics and side-effects up to one-year post-discharge</article-title>. <source>J Rehabil Med</source><year>2019</year>;<volume>51</volume>:<fpage>451</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.2340/16501977-2558</pub-id><pub-id pub-id-type="pmid">31032523</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pandharipande</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Girard</surname><given-names>TD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Co-Occurrence of post-intensive care syndrome problems among 406 survivors of critical illness</article-title>. <source>Crit Care Med</source><year>2018</year>;<volume>46</volume>:<fpage>1393</fpage>&#8211;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000003218</pub-id><pub-id pub-id-type="pmid">29787415</pub-id><pub-id pub-id-type="pmcid">PMC6095801</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hauschildt</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Seigworth</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kamphuis</surname><given-names>LA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Financial toxicity after acute respiratory distress syndrome: a national qualitative cohort study</article-title>. <source>Crit Care Med</source><year>2020</year>;<volume>48</volume>:<fpage>1103</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000004378</pub-id><pub-id pub-id-type="pmid">32697479</pub-id><pub-id pub-id-type="pmcid">PMC7387748</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Steinman</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Beizer</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>DuBeau</surname><given-names>CE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>How to use the American geriatrics Society 2015 beers criteria-A guide for patients, clinicians, health systems, and payors</article-title>. <source>J Am Geriatr Soc</source><year>2015</year>;<volume>63</volume>:<fpage>e1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.13701</pub-id><pub-id pub-id-type="pmid">26446776</pub-id><pub-id pub-id-type="pmcid">PMC5325682</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>